Results 191 to 200 of about 7,906 (281)

Association of Chartered Physiotherapists in Oncology and Palliative Care (ACPOPC) Southern Group Fatigue Study Day [PDF]

, 2005
Belchamber, C.A., Everett, Catherine
core  

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Monoclonal Antibody Therapies in Alzheimer's Disease: A Guide for Emergency Physicians. [PDF]

Emerg Med Australas
Wrigley S, Huynh ALH, Amadoru S, Zeimer H, Tan I, Woodward M, Braitberg G, Yates PA.   +7 more
europepmc   +1 more source

New directions for anti-emetic research

Annals of Oncology, 1994
openaire   +2 more sources

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients. [PDF]

Curr Treat Options Oncol
Mohindroo C, Ramirez RA.
europepmc   +1 more source

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Are two drugs better than one in advanced NSCLC? ABSTRACT Background Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC).
Junipearl Cheng, Charlotte McKay, Victoria Bray, Po Yee Yip, Annette Tognela, Peey Sei Kok   +5 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Component-based approach of enhanced recovery after surgery protocols in bariatric surgery: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Metabol Open
Almaski IEM, Alalwani YJ, Alshammari RS, Alassiri RMA, Jathmi SAS, Alhadi AM, Alzahrani AS, Alzahrani MA, Azzam AY, Maani TA.   +9 more
europepmc   +1 more source